三线免疫治疗后IV期胃癌的转化手术：一例病例报告
Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report.
作者信息
Evdokimova Sevindzh F, Kornietskaya Anna L, Bolotina Larisa V, Kolobayev Iliya V, Fedenko Alexander A, Kaprin Andrey D
机构信息
P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Peoples' Friendship University of Russia, Moscow, Russia.
出版信息
Front Oncol. 2024 Dec 6;14:1494669. doi: 10.3389/fonc.2024.1494669. eCollection 2024.
The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.
尽管有了全身治疗的进展，但IV期胃癌的5年总生存率仍低于10%。转化手术已被证明可改善对化疗有持久临床反应的患者的生存结果。我们报告了一例IV期胃癌患者的临床病例，该患者在三线治疗中接受帕博利珠单抗治疗后接受了转化手术。转化手术后该患者22个月未复发。
Zotero 插件